Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22815243 | 1.00 | PTPN1 (0.36) | PTPN1EPHX2ASAH1LMNACYP2C19 | |
| SCHEMBL14725897 | 0.89 | ALDH1A1 (0.40) | PTPN1EPHX2ASAH1LMNACYP2C19 | |
| SCHEMBL18608295 | 0.83 | PTPN1 (0.37) | PTPN1EPHX2ASAH1TSHRFAAH | |
| SCHEMBL14700212 | 0.83 | PTPN1 (0.37) | PTPN1EPHX2ASAH1TSHRFAAH | |
| SCHEMBL14700211 | 0.83 | PTPN1 (0.44) | PTPN1ASAH1LMNATSHRFAAH | |
| SCHEMBL23799216 | 0.81 | FAAH (0.55) | ASAH1LMNAFAAH | |
| SCHEMBL31549547 | 0.81 | PTPN1 (0.42) | PTPN1ASAH1LMNATSHRFAAH | |
| SCHEMBL22821571 | 0.81 | KDM4E (0.44) | EPHX2ASAH1LMNATSHRHPGD | |
| SCHEMBL29331428 | 0.81 | KDM4E (0.44) | EPHX2ASAH1LMNATSHRHPGD | |
| SCHEMBL23869653 | 0.81 | RECQL (0.34) | PTPN1EPHX2ASAH1LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | PTPN1 1342/4885EPHX2 2640/4885ASAH1 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.